CGEM ▲ +0.2% - Cullinan Therapeutics, Inc.
$CGEM - Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
08-OCT-2026 07:00 AM ET
Share this post
More filings for $CGEM
CGEM ▼ -0.1% - Cullinan Therapeutics, Inc.Oct 27, 2026CGEM ▼ -5.3% - Cullinan Therapeutics, Inc.Oct 1, 2026CGEM ▼ -0.5% - Cullinan Therapeutics, Inc.Sep 24, 2026CGEM ▼ -0.4% - Cullinan Therapeutics, Inc.Sep 21, 2026CGEM ▲ +0.8% - Cullinan Therapeutics, Inc.Sep 14, 2026CGEM ▼ -1.7% - Cullinan Therapeutics, Inc.Sep 10, 2026
View full $CGEM filing history →💬 Comments
Loading comments…
Leave a comment